Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Drug Res (Stuttg) ; 73(7): 369-377, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37276884

RESUMEN

The continuous implementation of Artificial Intelligence (AI) in multiple scientific domains and the rapid advancement in computer software and hardware, along with other parameters, have rapidly fuelled this development. The technology can contribute effectively in solving many challenges and constraints in the traditional development of the drug. Traditionally, large-scale chemical libraries are screened to find one promising medicine. In recent years, more reasonable structure-based drug design approaches have avoided the first screening phases while still requiring chemists to design, synthesize, and test a wide range of compounds to produce possible novel medications. The process of turning a promising chemical into a medicinal candidate can be expensive and time-consuming. Additionally, a new medication candidate may still fail in clinical trials even after demonstrating promise in laboratory research. In fact, less than 10% of medication candidates that undergo Phase I trials really reach the market. As a consequence, the unmatched data processing power of AI systems may expedite and enhance the drug development process in four different ways: by opening up links to novel biological systems, superior or distinctive chemistry, greater success rates, and faster and less expensive innovation trials. Since these technologies may be used to address a variety of discovery scenarios and biological targets, it is essential to comprehend and distinguish between use cases. As a result, we have emphasized how AI may be used in a variety of areas of the pharmaceutical sciences, including in-depth opportunities for drug research and development.


Asunto(s)
Inteligencia Artificial , Descubrimiento de Drogas , Diseño de Fármacos , Programas Informáticos , Computadores
3.
Drug Res (Stuttg) ; 72(5): 274-283, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35562101

RESUMEN

Nanotechnology-based nanomedicine offers several benefits over conventional forms of therapeutic agents. Moreover, nanomedicine has become a potential candidate for targeting therapeutic agents at specific sites. However, nanomedicine prepared by synthetic methods may produce unwanted toxic effects. Due to their nanosize range, nanoparticles can easily reach the reticuloendothelial system and may produce unwanted systemic effects. The nanoparticles produced by the green chemistry approach would enhance the safety profile by avoiding synthetic agents and solvents in its preparations. This review encompasses toxicity consideration of nanoparticles, green synthesis techniques of nanoparticle preparation, biomedical application of nanoparticles, and future prospects.


Asunto(s)
Sistemas de Liberación de Medicamentos , Nanopartículas , Sistemas de Liberación de Medicamentos/métodos , Nanomedicina/métodos , Nanotecnología/métodos , Preparaciones Farmacéuticas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...